Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMJ Open ; 6(5): e010765, 2016 05 04.
Article in English | MEDLINE | ID: mdl-27147385

ABSTRACT

OBJECTIVES: To investigate whether screening for malnutrition using the validated malnutrition universal screening tool (MUST) identifies specific characteristics of patients at risk, in patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). DESIGN: Cross-sectional study. SETTING: University Hospitals Coventry & Warwickshire NHS Trust; European Neuroendocrine Tumour Society Centre of Excellence. PARTICIPANTS: Patients with confirmed GEP-NET (n=161) of varying primary tumour sites, functioning status, grading, staging and treatment modalities. MAIN OUTCOME MEASURE: To identify disease and treatment-related characteristics of patients with GEP-NET who score using MUST, and should be directed to detailed nutritional assessment. RESULTS: MUST score was positive (≥1) in 14% of outpatients with GEP-NET. MUST-positive patients had lower faecal elastase concentrations compared to MUST-negative patients (244±37 vs 383±20 µg/g stool; p=0.018), and were more likely to be on treatment with long-acting somatostatin analogues (65 vs 38%, p=0.021). MUST-positive patients were also more likely to have rectal or unknown primary NET, whereas, frequencies of other GEP-NET including pancreatic NET were comparable between MUST-positive and MUST-negative patients. CONCLUSIONS: Given the frequency of patients identified at malnutrition risk using MUST in our relatively large and diverse GEP-NET cohort and the clinical implications of detecting malnutrition early, we recommend routine use of malnutrition screening in all patients with GEP-NET, and particularly in patients who are treated with long-acting somatostatin analogues.


Subject(s)
Antineoplastic Agents/adverse effects , Gastrointestinal Neoplasms/drug therapy , Hormones/adverse effects , Malnutrition/chemically induced , Neuroendocrine Tumors/drug therapy , Pancreatic Neoplasms/drug therapy , Somatostatin/adverse effects , Antineoplastic Agents/therapeutic use , Biomarkers/metabolism , Cross-Sectional Studies , England/epidemiology , Female , Gastrointestinal Neoplasms/complications , Gastrointestinal Neoplasms/metabolism , Hormones/therapeutic use , Humans , Male , Middle Aged , Neuroendocrine Tumors/complications , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/metabolism , Practice Guidelines as Topic , Somatostatin/analogs & derivatives , Somatostatin/therapeutic use , Treatment Outcome
2.
BMJ Case Rep ; 20112011 Aug 19.
Article in English | MEDLINE | ID: mdl-22678732

ABSTRACT

An 18-year-old man presented with a 2 day history of breathlessness and left-sided chest pain, with no preceding trauma. He had no medical history of note, and had never smoked. He was in hypovolaemic shock, with Hb of 8.1 g/dl, and received fluid resuscitation. Chest x-ray (CXR) revealed left-sided hydropneumothorax, with the effusion of blood-consistency on CT thorax. Tube thoracostomy drained 1.7 litres of blood immediately. He remained haemodynamically stable after 4 units of blood transfusion on the first day with post-transfusion Hb 11 g/dl. Following cardiothoracic surgeon advice, tube was removed on day 5 draining total of 3.5 litres, with good response clinically and radiologically. Patient was well when followed up at 1 week after hospital discharge, with no recurrence and complete re-expansion of left lung on CXR.


Subject(s)
Hemopneumothorax/diagnostic imaging , Hemopneumothorax/surgery , Adolescent , Chest Pain/etiology , Drainage , Dyspnea/etiology , Hemopneumothorax/complications , Humans , Male , Shock/etiology , Shock/therapy , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...